EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Risk of severe cardiovascular events following COPD exacerbations: results from the EXACOS-CV study in Spain

Salud Santos, Nicolás Manito, Joaquín Sánchez-Covisa, Ignacio Hernández, Carmen Corregidor, Luciano Escudero, Kirsty Rhodes, Clementine Nordon

Revista Española de Cardiología (English Edition) · 2025-02 · 78 (2) · 138-150

DOI: 10.1016/j.rec.2024.06.003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Revista Española de Cardiología (English Edition), 2025-02. Verfasst von Salud Santos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Neumología, Hospital Universitario de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barce…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND OBJECTIVES: This real-world study-the first of its kind in a Spanish population-aimed to explore severe risk for cardiovascular events and all-cause death following exacerbations in a large cohort of patients with chronic obstructive pulmonary disease (COPD). METHODS: We included individuals with a COPD diagnosis code between 2014 and 2018 from the BIG-PAC health care claims database. The primary outcome was a composite of a first severe cardiovascular event (acute coronary syndrome, heart failure decompensation, cerebral ischemia, arrhythmia) or all-cause death following inclusion in the cohort. Time-dependent Cox proportional hazards models estimated HRs for associations between exposed time periods (1-7, 8-14, 15-30, 31-180, 181-365, and >365 days) following an exacerbation of any severity, and following moderate or severe exacerbations separately (vs unexposed time before a first exacerbation following cohort inclusion). RESULTS: During a median follow-up of 3.03 years, 18 901 of 24 393 patients (77.5%) experienced ≥ 1 moderate/severe exacerbation, and 8741 (35.8%) experienced the primary outcome. The risk of a severe cardiovascular event increased following moderate/severe COPD exacerbation onset vs the unexposed period, with rates being most increased during the first 1 to 7 days following exacerbation onset (HR, 10.10; 95%CI, 9.29-10.97) and remaining increased >365 days after exacerbation onset (HR, 1.65; 95%CI, 1.49-1.82). CONCLUSIONS: The risk of severe cardiovascular events or death increased following moderate/severe exacerbation onset, illustrating the need for proactive multidisciplinary care of patients with COPD to prevent exacerbations and address other cardiovascular risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesPulmonary Disease, Chronic ObstructiveAgedFemaleHumansMaleMiddle AgedCause of DeathDisease ProgressionFollow-Up StudiesIncidenceRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexSpain

Stichwörter der Autor:innen

AgudizaciónCardiopulmonarCardiopulmonaryCardiovascular riskChronic obstructive pulmonary diseaseEnfermedad pulmonar obstructiva crónicaEstudio observacionalExacerbationMortalidadMortalityObservational studyRiesgo cardiovascular

Autor:innen und Institutionen

  • Servicio de Neumología, Hospital Universitario de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Servicio de Cardiología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Medical Department, Evidence Generation, AstraZeneca, Madrid, Spain. Electronic address: joaquin.sanchez-covisa@astrazeneca.com.
  • Atrys Health, HEOR, Madrid, Spain.
  • Medical Department, Medical Affairs, AstraZeneca, Madrid, Spain.
  • Real World Science & Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.

Förderung

  • AstraZeneca

Zitieren

APA

Santos, S., Manito, N., Sánchez-Covisa, J., Hernández, I., Corregidor, C., Escudero, L., Rhodes, K., & Nordon, C. (2025). Risk of severe cardiovascular events following COPD exacerbations: results from the EXACOS-CV study in Spain. Revista Española de Cardiología (English Edition), 78(2), 138-150. https://doi.org/10.1016/j.rec.2024.06.003

Vancouver

Santos S, Manito N, Sánchez-Covisa J, Hernández I, Corregidor C, Escudero L, et al. Risk of severe cardiovascular events following COPD exacerbations: results from the EXACOS-CV study in Spain. Revista Española de Cardiología (English Edition). 2025;78(2):138-150. doi:10.1016/j.rec.2024.06.003

BibTeX
@article{Santos2025,
  author = {Santos, Salud and Manito, Nicolás and Sánchez-Covisa, Joaquín and Hernández, Ignacio and Corregidor, Carmen and Escudero, Luciano and Rhodes, Kirsty and Nordon, Clementine},
  title = {Risk of severe cardiovascular events following COPD exacerbations: results from the EXACOS-CV study in Spain},
  journal = {Revista Española de Cardiología (English Edition)},
  year = {2025},
  volume = {78},
  number = {2},
  pages = {138--150},
  doi = {10.1016/j.rec.2024.06.003}
}
Kostenlos starten →